Business
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier - WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it will present new preclinical data demonstrating the ability of the FORCE platform to cross the blood-brain barrier (BBB) and
About this update from Dyne Therapeutics, Inc.
[{"type":"image","alt":"Dyne Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Dyne Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/e818a029eb02ef26c3902e74a3e0ec39"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/k23yvwJif2jshK1r_uNGyw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNw--/https://media.zenfs.com/en/globenewswire.com/e818a029eb02ef26c3902e74a3e0ec39","width":300,"height":91}},"lazy":false},{"type":"text","content":"- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier -","length":125,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it will present new preclinical data demonstrating the ability of the FORCE platform to cross the blood-brain barrier (BBB) and enable robust knockdown of MAPT RNA in the central nervous system (CNS) at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting being held May 11-15, 2026, in Boston, MA, and virtually.","length":588,"tagName":"p"},{"type":"text","content":"“While we maintain our focus on advancing our clinical programs in DMD and DM1, as well as our broader neuromuscular pipeline, we are also exploring additional applications where the differentiated capabilities of our FORCE platform, along with further iterations, could enable potentially transformative therapies for patients, including for neurological diseases,” said Oxana Beskrovnaya, Ph.D., chief innovation officer of Dyne. “Building on previous studies, these data highlight the ability of our clinically validated Fab to enable robust activity in the CNS. Additionally, for the first time, we are presenting data showing the potential to further optimize our Fab for enhanced CNS delivery, which resulted in even more robust knockdown of a well-characterized CNS target.”","length":781,"tagName":"p"},{"type":"text","content":"Preclinical Study Details","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Preclinical studies were performed using two compounds, Conjugate 1 ...